<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430351</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0374</org_study_id>
    <secondary_id>NCI-2011-03038</secondary_id>
    <secondary_id>2011-0374</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01430351</nct_id>
  </id_info>
  <brief_title>Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy</brief_title>
  <official_title>A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of combination chemotherapy in
      treating patients with glioblastoma multiforme after radiation therapy. Drugs used in
      chemotherapy, such as temozolomide, memantine hydrochloride, and metformin hydrochloride,
      work in different ways to stop the growth of tumor cells, either by killing them or stopping
      them from dividing. Mefloquine may help temozolomide, memantine hydrochloride, and metformin
      hydrochloride kill more cancer cells by making tumor cells more sensitive to the drug. Giving
      more than one drug (combination chemotherapy) may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and tolerability of temozolomide (TMZ) in combination with
      metformin (metformin hydrochloride) (MFRMN) and/or mefloquine (MFLOQ) and/or memantine
      (memantine hydrochloride) (MEMTN) in patients receiving adjuvant therapy after completing
      external beam radiotherapy (XRT) in combination with chemotherapy for newly diagnosed
      glioblastoma multiforme (GBM).

      SECONDARY OBJECTIVES:

      I. To determine the median progression free survival (PFS); 6, 12, and 18 month PFS; and
      median overall survival (OS) in patients treated with temozolomide and a combination of
      metformin and/or mefloquine and/or memantine.

      OUTLINE: This is a dose-escalation study. Patients are randomized to 1 of 8 different
      treatment arms.

      ARM 1: Patients receive temozolomide orally (PO) once daily (QD) on days 1-5.

      ARM 2: Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO twice
      daily (BID).

      ARM 3: Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of
      week 1 and then days 2, 4, and 6 every other week.

      ARM 4: Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.

      ARM 5: Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and
      mefloquine PO QD as in Arm 3.

      ARM 6: Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and
      metformin hydrochloride PO BID as in Arm 4.

      ARM 7: Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and
      metformin hydrochloride PO BID as in Arm 4.

      ARM 8: Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2,
      metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.

      In all arms, courses repeat every 28 days for up to 24 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 14, 2011</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>During first 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <condition>Supratentorial Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 (temozolomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO QD on days 1-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (temozolomide, memantine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (temozolomide, mefloquine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (temozolomide, metformin hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 (temozolomide, memantine hydrochloride, mefloquine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 (temozolomide, memantine hydrochloride, metformin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 (temozolomide, mefloquine, metformin hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm 3 (temozolomide, mefloquine)</arm_group_label>
    <arm_group_label>Arm 5 (temozolomide, memantine hydrochloride, mefloquine)</arm_group_label>
    <arm_group_label>Arm 7 (temozolomide, mefloquine, metformin hydrochloride)</arm_group_label>
    <arm_group_label>Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm 2 (temozolomide, memantine hydrochloride)</arm_group_label>
    <arm_group_label>Arm 5 (temozolomide, memantine hydrochloride, mefloquine)</arm_group_label>
    <arm_group_label>Arm 6 (temozolomide, memantine hydrochloride, metformin)</arm_group_label>
    <arm_group_label>Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)</arm_group_label>
    <other_name>Ebixia</other_name>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm 4 (temozolomide, metformin hydrochloride)</arm_group_label>
    <arm_group_label>Arm 6 (temozolomide, memantine hydrochloride, metformin)</arm_group_label>
    <arm_group_label>Arm 7 (temozolomide, mefloquine, metformin hydrochloride)</arm_group_label>
    <arm_group_label>Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)</arm_group_label>
    <other_name>APO-Metformin</other_name>
    <other_name>Cidophage</other_name>
    <other_name>Dimefor</other_name>
    <other_name>Glifage</other_name>
    <other_name>Glucoformin</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage ER</other_name>
    <other_name>Metformin HCl</other_name>
    <other_name>Riomet</other_name>
    <other_name>Siofor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm 1 (temozolomide)</arm_group_label>
    <arm_group_label>Arm 2 (temozolomide, memantine hydrochloride)</arm_group_label>
    <arm_group_label>Arm 3 (temozolomide, mefloquine)</arm_group_label>
    <arm_group_label>Arm 4 (temozolomide, metformin hydrochloride)</arm_group_label>
    <arm_group_label>Arm 5 (temozolomide, memantine hydrochloride, mefloquine)</arm_group_label>
    <arm_group_label>Arm 6 (temozolomide, memantine hydrochloride, metformin)</arm_group_label>
    <arm_group_label>Arm 7 (temozolomide, mefloquine, metformin hydrochloride)</arm_group_label>
    <arm_group_label>Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)</arm_group_label>
    <other_name>CCRG-81045</other_name>
    <other_name>Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-</other_name>
    <other_name>M &amp; B 39831</other_name>
    <other_name>M and B 39831</other_name>
    <other_name>Methazolastone</other_name>
    <other_name>RP-46161</other_name>
    <other_name>SCH 52365</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>Temomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven supratentorial glioblastoma or gliosarcoma (World
             Health Organization [WHO] grade IV astrocytoma) will be eligible for this protocol;
             patients will be eligible if the original histology was low-grade glioma and a
             subsequent histological diagnosis of glioblastoma or gliosarcoma is made prior to any
             definitive treatment (radiotherapy, chemotherapy)

          -  All patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study; patients must be registered prior to treatment
             with study drug

          -  Patients must have a Karnofsky performance status (KPS) of &gt;= 60

          -  White blood cells (WBC) &gt;= 3,000/ul (performed within 14 days prior to registration)

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3 (performed within 14 days prior to
             registration)

          -  Platelet count of &gt;= 100,000/mm^3 (performed within 14 days prior to registration)

          -  Hemoglobin &gt;= 10 gm/dl (eligibility level for hemoglobin may be reached by
             transfusion) (performed within 14 days prior to registration)

          -  Serum glutamic oxaloacetic transaminase (SGOT) &lt; 2 times upper limit of normal (ULN)
             (performed within 14 days prior to registration)

          -  Bilirubin &lt; 2 times ULN (performed within 14 days prior to registration)

          -  Creatinine &lt; 1.5 mg/dL (performed within 14 days prior to registration)

          -  For patients on mefloquine arm, a baseline electrocardiogram (EKG) without evidence of
             prolonged corrected QT (QTc) interval &gt; 450 ms or clinically significant arrhythmia
             must be obtained within 14 days prior to registration

          -  A brain scan should be performed within 14 days prior to registration and steroid
             dosing should be stable or decreasing for at least 5 days; if the steroid dose is
             increased between the date of imaging and registration a new baseline magnetic
             resonance (MR)/computed tomography (CT) is required; the same type of scan, i.e.,
             magnetic resonance imaging (MRI) or CT must be used throughout the period of protocol
             treatment for tumor measurement

          -  Patients must have completed standard radiation therapy with concurrent TMZ and must
             not have evidence of progressive disease on post treatment imaging

          -  Women of childbearing potential must have a negative serum or urine beta-human
             chorionic gonadotropin (B-HCG) pregnancy test documented within 72 hours of start of
             therapy

          -  Patients must be registered on the study within 5 weeks of completion of concurrent
             chemoradiation

        Exclusion Criteria:

          -  Patients must not have any significant medical illnesses that, in the investigator's
             opinion, cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy

          -  For mefloquine arm, patients with evidence of QTc interval &gt; 450 ms or clinically
             significant arrhythmia on baseline EKG obtained within 14 days of registration will be
             ineligible for protocol enrollment

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years, are ineligible

          -  Patients must not have active infection or serious intercurrent medical illness

          -  Patients must not be pregnant/breast feeding and must agree to practice adequate
             contraception (acceptable forms of birth control include condom with spermicide and/or
             diaphragm with spermicide, and non-barrier contraception such as tubal ligation,
             vasectomy, oral contraceptives, implanted levonorgestrel, vaginal hormonal
             contraceptive ring)

          -  Patients must not have any disease that will obscure toxicity or dangerously alter
             drug metabolism; patients with a history of psychosis/schizophrenia or cardiac disease
             requiring beta-blocker treatment (unable to change medication to non-beta blocker),
             anti-malarial drugs, or quinine or quinidine will not be eligible for enrollment to a
             mefloquine containing arm; patients who are on active treatment with one of the study
             drugs at the time of evaluation will not be eligible for enrollment to an arm
             containing that study drug

          -  For mefloquine arm, patients must not be on enzyme inducing anticonvulsants (EIAED);
             if the treating physician elects to change the medication to a non-enzyme inducing
             agent, a 2-week wash out period will be required after stopping EIAED prior to
             initiation of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Penas-Prado</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Mefloquine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

